Russell Investments Group Ltd. Takes $133,000 Position in Syros Pharmaceuticals Inc (SYRS)
Russell Investments Group Ltd. purchased a new stake in shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 9,025 shares of the company’s stock, valued at approximately $133,000.
Other institutional investors have also made changes to their positions in the company. California State Teachers Retirement System lifted its holdings in Syros Pharmaceuticals by 131.3% during the 2nd quarter. California State Teachers Retirement System now owns 22,200 shares of the company’s stock valued at $357,000 after purchasing an additional 12,600 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Syros Pharmaceuticals by 157.9% during the second quarter. Bank of New York Mellon Corp now owns 30,024 shares of the company’s stock worth $483,000 after buying an additional 18,382 shares in the last quarter. Ark Investment Management LLC lifted its holdings in shares of Syros Pharmaceuticals by 114.7% during the second quarter. Ark Investment Management LLC now owns 17,705 shares of the company’s stock worth $285,000 after buying an additional 9,460 shares in the last quarter. FMR LLC lifted its holdings in shares of Syros Pharmaceuticals by 11.9% during the second quarter. FMR LLC now owns 3,926,998 shares of the company’s stock worth $63,185,000 after buying an additional 418,061 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Syros Pharmaceuticals by 189.6% during the second quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock worth $6,156,000 after buying an additional 250,507 shares in the last quarter. 57.96% of the stock is owned by institutional investors and hedge funds.
In related news, insider Jeremy P. Springhorn purchased 15,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was acquired at an average price of $9.08 per share, with a total value of $136,200.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Srinivas Akkaraju purchased 109,774 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The stock was bought at an average cost of $9.03 per share, with a total value of $991,259.22. The disclosure for this purchase can be found here. 33.60% of the stock is owned by insiders.
Syros Pharmaceuticals Inc (NASDAQ:SYRS) opened at $10.39 on Wednesday. The company has a market capitalization of $273.22 and a PE ratio of -5.97. Syros Pharmaceuticals Inc has a 52 week low of $6.30 and a 52 week high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.53). equities research analysts predict that Syros Pharmaceuticals Inc will post -2.12 earnings per share for the current fiscal year.
SYRS has been the subject of a number of research reports. Oppenheimer set a $28.00 target price on Syros Pharmaceuticals and gave the stock a “buy” rating in a report on Monday. Zacks Investment Research raised Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Friday, January 5th. Cowen reissued a “buy” rating on shares of Syros Pharmaceuticals in a report on Monday, December 11th. HC Wainwright reissued a “hold” rating and set a $10.00 target price on shares of Syros Pharmaceuticals in a report on Thursday, December 21st. Finally, Roth Capital initiated coverage on Syros Pharmaceuticals in a report on Monday, October 23rd. They set a “neutral” rating and a $15.00 target price for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $22.23.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Want to see what other hedge funds are holding SYRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syros Pharmaceuticals Inc (NASDAQ:SYRS).
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.